Sunesis Pharmaceuticals Inc said the U.S. Food and Drug Administration called for more clinical evidence before considering approval for its cancer drug, sending the company’s shares down 60 percent in after-market trading. The drug, vosaroxin, failed a late-stage trial in October as it did not significantly improve the overall survival of patients compared with a […]